Evotec turns to automation and continuous bioprocessing with new facility in France

By Rachel Arthur

- Last updated on GMT


Related tags France Continuous bioprocessing

Evotec will build a biologics manufacturing facility in Toulouse, France: marking the company’s first commercial biomanufacturing facility in Europe.

Named J.POD 2EU, the site will use tech from Evotec subsidiary Just-Evotec Biologics: which utilizes small, automated, highly intensified and continuous bioprocessing operations housed inside autonomous cleanrooms.

Construction of the €150m ($181.8m) site will start in H2, 2021. Once operational in 2023, it will be able to product therapeutic antibodies, including those related to infectious diseases such as COVID-19.

Situated at Evotec’s Campus Curie, build-up of J.POD2 EU will be supported with up to €50m ($60.6m) from the French government and regional and local governments. Campus Curie was also recently expanded through the acquisition of Biopark by Sanofi.

The French site will be Evotec’s second cGMP biomanufacturing facility. The construction of the first US site, ‘J.POD 1 US’, in Redmond, Washington, is expected to be fully operational later this year.

Dr Craig Johnstone, Chief Operating Officer of Hamburg-headquartered Evotec, said: “With Just – Evotec Biologics, Evotec has world-leading expertise for biologics discovery, process development and production.

"We are very pleased with the market response and demand for J.POD 1 US even ahead of completion, so this second J.POD facility is a significant expansion of our capacity of disruptive and transformational bioproduction.

“In addition, the flexibility of the modular J.POD setup also creates potential opportunities for cell and gene therapy biomanufacturing. These modalities, which are also an integral part of our data-driven R&D Autobahn to Cures, therefore also stand to benefit from this new facility.”


Related topics Upstream Processing Facilities

Related news

Show more

Related products

Trends in Biopharmaceutical Raw Material Selection

Trends in Biopharmaceutical Raw Material Selection

Actylis – The Partner of Choice | 31-Jan-2023 | Business Advice

Join us as our in-house experts, along with Cecile Bellamy from Pfizer, discuss current and future trends in biopharmaceutical raw material selection.

Liposomal and Nanoparticle Technology

Liposomal and Nanoparticle Technology

Pfizer CentreOne | 18-Nov-2022 | Technical / White Paper

Medical science is continuously searching for better ways to administer drugs into the body and to maximize the therapeutic effectiveness of the drugs...

The Reagents Behind Much of Molecular Biology

The Reagents Behind Much of Molecular Biology

Thermo Fisher Scientific | 25-Jul-2022 | Case Study

The ability to amplify, modify and fabricate DNA is fundamental to modern molecular biology. Why do so many researchers take their constituent parts for...

Related suppliers

Follow us


View more